Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
Portfolio Pulse from
Evoke Pharma emphasizes GIMOTI as a key treatment for gastroparesis as the FDA announces the end of domperidone supply by early 2025. GIMOTI is the only approved drug shown to reduce hospitalizations and related costs compared to oral metoclopramide.
December 19, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evoke Pharma's GIMOTI is highlighted as a leading treatment for gastroparesis, especially as domperidone supply is expected to end by 2025. This positions GIMOTI as a critical solution, potentially increasing its market demand.
With the FDA's update on the end of domperidone supply, GIMOTI becomes the only approved drug for gastroparesis that reduces hospitalizations and costs. This could lead to increased demand and market share for Evoke Pharma, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100